v3.25.4
ACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS - Additional Disclosures of our Significant Expenses Within Research and Development (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Schedule of Research and Development Expense [Line Items]      
Research and development $ 9,951 $ 11,159 $ 9,299
Other Research      
Schedule of Research and Development Expense [Line Items]      
Research and development 1,341 1,522 1,557
Drug Development      
Schedule of Research and Development Expense [Line Items]      
Research and development 4,550 4,495 3,835
Other      
Schedule of Research and Development Expense [Line Items]      
Research and development $ 4,060 $ 5,142 $ 3,907